Sandra Yeh, MD
Ophthalmology · Springfield, ILNPI 1841248838
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.5% of the total across 163 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Alcon at 58.0% of the total.
Across 163 payments — averaging $48.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$5K
- Johnson & Johnson Surgical Vision, Inc.$1K
- Tarsus Pharmaceuticals, Inc.$401
- AbbVie$300
- Optos, Inc.$157
- Novartis$151
- plus $1K from 19 others
Across 4 payments — averaging $47,368 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$173K
- Genentech, Inc.$16K
What the payments were for
- Travel & lodging$5928%
- Food & beverage$7,11990%
- Entertainment$1572%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 64 | $4,565 |
| Johnson & Johnson Surgical Vision, Inc. | 27 | $1,214 |
| Tarsus Pharmaceuticals, Inc. | 8 | $401 |
| AbbVie(2 entities) | 11 | $300 |
| Optos, Inc. | 4 | $157 |
| Novartis | 9 | $151 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $122 |
| Glaukos Corporation | 2 | $113 |
| Beaver-visitec International, Inc. | 1 | $111 |
| Sun Pharmaceutical Industries Inc. | 5 | $85 |
| Carl Zeiss Meditec, Inc. | 1 | $82 |
| Alimera Sciences, Inc. | 5 | $75 |
| Carl Zeiss Meditec USA, Inc. | 1 | $62 |
| Kala Pharmaceuticals, Inc. | 3 | $61 |
| Bausch & Lomb Americas Inc. | 3 | $61 |
| LKC Technologies, Inc. | 1 | $55 |
| Rxsight Inc | 2 | $49 |
| Mallinckrodt Hospital Products Inc. | 1 | $36 |
| Oyster Point Pharma, Inc. | 1 | $30 |
| Coopervision Inc. | 2 | $29 |
| Johnson & Johnson Vision Care, Inc. | 2 | $28 |
| Amgen | 1 | $26 |
| Genentech USA, Inc. | 1 | $21 |
| Rayner Intraocular Lenses Limited | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LenSx$759
- Clareon$711
- Wavelight Refractive Suite$592
- Unity$562
- ARGOS$552
- Voyager DSLT$287
- XDEMVY$248
- Centurion$246
- PanOptix$151
- Tecnis IOL$141
- Hydrus Microstent$141
- Rocklatan$125
- CATALYS SYSTEM$120
- DURYSTA$107
- P200DTx$104
- P200T$104
- P200TE$104
- P200TxE$104
How this compares
$7,868 in reported general payments places this provider in the 85th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 18 | $11,613 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 17 | $4,318 |
| Travoprost | 11 | $1,231 |
| Latanoprost | 88 | $1,088 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 28 | $444 |
| Timolol Maleate | 54 | $378 |
| Brimonidine Tartrate | 11 | $93 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $300 | $11,61318 claims |
| AlconSimbrinza | $4,565 | $4,31817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Springfield
- Lisa NijmSpringfield$1.7M
- Ramanath BhandariSpringfield$112K
- Robert LowenthalSpringfield$31K
- Seenu HariprasadChicago$2.3M
- Kathleen MornoNorth Riverside$1.2M
- Veeral ShethOak Forest$716K
- James KatzDes Plaines$642K
- Mitchell JacksonLake Villa$584K
- David LubeckHomewood$575K
- Parag MajmudarHighland Park$451K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.